China Biopharma Acquires RNAi Innovator Hejiya for RMB 1.2 Billion to Advance siRNA Pipeline
Sino Biopharm
Pharmaceutical R&D Developer
Hygieia
Small Interfering RNA (siRNA) Drug Developer
On January 13, Sino Biopharmaceutical Co., Ltd. issued an announcement,Will beTotal Price of 1.2 Billion RMB: Full Acquisition of Hygieia, an Innovative Pharmaceutical Company in China's Small Interfering RNA (siRNA) Field. It is reported that,This is the first major acquisition in China's small nucleic acid field initiated by a large pharmaceutical company.
Hygieia was founded in2018Year, is a company focused onsiRNAA pioneering biopharmaceutical company in the research and development of innovative drugs. The R&D team led by Cui Kunyuan has expertise in the development of small nucleic acid drugs.20Years of professional experience, achieved50Multiple core patents have been built up from target discovery to clinical concept validation (POC) Integrated innovative drug development system. Relying on6In China/External Delivery Platform, Hygieia is considered to be a leader in the small nucleic acid field in China.“Industry Dark Horse”。
——MVIPLiver-targeting Platform: The world's first and currently the only clinically validated platform capable of achieving“One Shot, Once a Year”Long-acting drug deliverysiRNADelivery technology platform. Both in vitro and in vivo models have shown superior delivery efficiency and effectiveness compared to existing similar platforms, and it is the first in China to receive global patent authorization.siRNADelivery technology platform, whose efficiency, safety, and long-acting properties have been validated across multiple clinical pipelines.
——DDPDual-target Delivery Platform: Capable of Simultaneous Dual-target DeliverysiRNA, achieve“1+1>2”The synergistic therapeutic effect can be further enhanced in the future by integrating different tissue-targeting platforms to develop treatments for complex or refractory diseases mediated by multiple targets and mechanisms, showcasing significant technological disruption.
——NSDPNeuro-targeting Platform: Forward-looking Layout in the Field of Neurological Disease Delivery, FillingCNS(Central Nervous System) andPNS(Unmet clinical needs in peripheral nerves,)2026Products will soon enter the clinical stage, expanding the pipeline to a broader range of disease areas.
Currently,Hygieia has4Products Enter Clinical Stage, Exceeding20The project is in the preclinical stage,And has been reached2The external authorization covers three major chronic disease fields in the R&D pipeline: weight loss and metabolism, cardiovascular and cerebrovascular, and nervous system, all of which are equipped with f.irst-in-classWith best-in-classPotential.
Hygieia Based onMVIPDelivery Platform Self-developedKylo-11Is the world's first to achieve“One Shot, One Year”Long-acting reductionLp(a)Drug, a single subcutaneous injection can achieve95%OfLp(a)The reduction, with an expected efficacy duration of over one year, a dosage much lower than similar products, higher safety, and greater medication convenience, as well as best-in-classPotential.
Kylo-11Conducting international multicenter studies in China and the USIIPhase clinical trial, and on2025Year10Completed the first patient dosing in the month, being the fastest-progressing treatment in China for highLp(a)Small nucleic acid products for hematology.
Sino Biopharm in Respiratory, Hepatic Diseases/Rich layouts in the fields of metabolism and autoimmune have been established. Through this acquisition, not only is the construction of the next-generation innovative pipeline in the cardiovascular and cerebrovascular field completed, but the layout in the weight-loss metabolism field is also further improved, broadening the treatment map in the major chronic disease areas.
Except forKylo-11Hygieia's projects that have entered the clinical stage also include: treatment for hypertriglyceridemia (HTG`) and Familial Hyperchylomicronemia (`FCS) ofAPOC3 siRNA（Kylo-12), the world's first through conjugationGalNAcAchieving Differential Liver TargetingTHR-βSmall Molecule Agonist (Kylo-0603), etc.
"Frontier π" Column
PharmaCube Pro